Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: A prospective study of 142 patients

Journal of Gastroenterology

Volumn 38, Issue 11, 2003, Pages 1042-1048

  Farsakh, Niazy Abu ^a,b  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b NONE   (Jordan)

Author keywords

Endoscopy; Esophagitis; Heartburn; Lansoprazole; Outcome; Reflux

Indexed keywords

LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; ERADICATION THERAPY; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; STOMACH FUNDOPLICATION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGITIS; FEMALE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; RANITIDINE; TREATMENT OUTCOME;

EID: 0346882822     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1194-8     Document Type: Article

References (36)

1. Abu Farsakh N, Saadeh A, Rawashdeh M, Abu Farsakh H. Dyspepsia in the general population in Jordan. Indian J Gastroenterol 2000;19:68-70.
2. Heading RC. Epidemiology of oesophageal reflux disease. Scand J Gastroenterol 1989;24(Suppl 168):33-7.
3. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
4. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993;199:18-21.
5. Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995;40:1098-104.
6. Galmiche JP, Bruley des Varannes S. Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994;201:62-8.
7. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastrooesophageal reflux disease without oesophagitis. Gut 1991;32: 845-8.
8. Schindlebeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992;33:1016-9.
9. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997;9: 1161-7.
10. Stein HJ, De Meester TR. Who benefits from antireflux surgery? World J Surg 1992;6:313-9.
11. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut 1999;44(Suppl 2):S1-16.
12. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160: 1810-6.
13. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67.
14. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
15. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
16. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
17. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole versus ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994:35:590-8.
18. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schutz T, Mowinckel P, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999:319:550-3.
19. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
20. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999;94:92-7.
21. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
22. Dent J, Jones R, Kahrilas P, Tally NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-7.
23. Tytgat GN, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-80.
24. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr. Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999;94:628-31.
25. Howard PJ, Maher L, Pryde A, Heading RC. Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut 1991;32:128-32.
26. Johnston BT, McFarland RJ, Collins JS, Love AH. Symptom index as a marker of gastro-oesophageal reflux disease. Br J Surg 79:1054-5.
27. Petersen H. The prevalence of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1995;211:5-6.
28. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that require aggressive therapy. Am J Gastroenterol 1995;90:1053-7.
29. Raiha I, Heietanen E, Sourander L. Symptoms of gastroesophageal reflux disease in elderly people. Age Ageing 1991;20:368-73.
30. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-92.
31. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
32. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95: 903-12.
33. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-9.
34. Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, et al. The cost of long term therapy for gastrooesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 2001;49:488-94.
35. Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost utility analysis. Gastroenterology 1997;112: 1078-86.
36. Abu Farsakh NA, Roweily E, Rababaa M, Butchoun R. Evaluation of the upper gastrointestinal tract in uremic patients undergoing hemodialysis. Nephrol Dial Transplant 1996;11:847-50.